By Carolina Lima | Published on November 4, 2025 | 3 min read
Prostate
cancer (PCa) remains one of the most prevalent cancers in men worldwide, often progressing
to treatment-resistant stages. In recent years, curcumin—a polyphenolic
compound derived from Curcuma longa has gained attention for its
multi-targeted anticancer properties. A recent systematic review published in BMC
Cancer (2025) highlights preclinical evidence on how curcumin acts at the
molecular level in PCa and how nanotechnology improves its therapeutic
potential.
Molecular
targets and mechanisms
Curcumin
modulates several key pathways in PCa:
- PI3K/Akt/mTOR axis, a key driver of prostate
cancer growth, particularly in PTEN-deficient tumours, where the PTEN
gene is lost or inactivated. PTEN normally acts as a tumour suppressor, so its
absence leads to hyperactive signalling. Nanoparticle curcumin formulations,
such as Theracurmin®, effectively suppresses this pathway, reducing cell
proliferation.
NF-κB: when is overactive, promotes the expression of
pro-inflammatory cytokines like TNF-α, fostering a tumour-supportive environment and enabling cancer cells to
resist apoptosis. Curcumin downregulates NF-κB and these cytokines, promoting apoptosis and
reducing tumour-promoting inflammation.
Androgen receptor (AR), essential for PCa growth in both
hormone-sensitive and therapy-resistant stages. AR is activated by androgens
like testosterone and dihydrotestosterone. Curcumin and its derivatives, such
as H10, inhibit enzymes like 17β-HSD3 (necessary in testosterone biosynthesis) lowering
androgen levels and AR activity, which suppresses tumor growth and PSA
expression. This makes curcumin promising adjunct to androgen deprivation
strategies.
Apoptosis and Necroptosis: curcumin activates both intrinsic (Bax,
caspase-3) and extrinsic (DR4/DR5) apoptotic pathways and induces
necroptosis in acidity-adapted PCa cells—cells conditioned to survive in
a tumour-mimic microenvironment. This dual cell-death mechanism targets cancer
cells while sparing healthy tissue.
Anti-metastatic
and metabolic effects
In
preclinical models, curcumin consistently triggers apoptosis, halts the cell
cycle (at G1 or G2/M) and reduces cancer cell migration and invasion by
suppressing epithelial–mesenchymal transition (EMT) —a process where
cancer cells lose their epithelial traits and gain mesenchymal features,
increasing motility and invasiveness. Curcumin also inhibits angiogenesis and disrupts
cancer metabolism by blocking PDHA1, a critical enzyme for
mitochondrial energy production.
Nanotechnology:
boosting bioavailability
One of the
major challenges in curcumin therapy is its poor solubility and
bioavailability. Nanotechnology offers solutions :
- Theracurmin®: a nanoparticle formulation
that improves bioavailability over 40-fold.
- Dextran-curcumin nanoparticles: Increase ROS production which
promotes oxidative stress and cancer cell death while blocking EMT.
- Scorpion venom-conjugated
phytosomes: Amplify
apoptosis and mitochondrial dysfunction.
- PLGA-based nanoparticles: More effectively block
steroid biosynthesis and androgen production than free curcumin.
Synergistic therapies and photodynamic potential
Curcumin’s
efficacy is further amplified when combined with:
- Chemotherapeutics: docetaxel and cisplatin
enhance apoptosis and tumour suppression.
- Natural compounds: quercetin and carnosic
acid synergize with curcumin to modulate ROS, NF-κB, and MAPK pathways.
Light irradiation: boosts curcumin’s cytotoxicity at
ultralow doses, supporting its role in photodynamic therapy.
Conclusion:
a safer, smarter ally in prostate cancer care
Curcumin demonstrates
powerful, multi-targeted anticancer activity in prostate cancer, acting on key
pathways such as PI3K/Akt/mTOR, NF-κB, AR signaling, and EMT —all
while maintaining a low toxicity profile.
But to
translate this potential into real patient benefit, future research must refine
its formulation improving bioavailability and identify which patients are most
likely to respond.
Rigorous clinical trials are essential to validate its
safety and efficacy.
Thanks to
its
broad-spectrum activity and excellent safety record, curcumin may also be
considered as a
preventive dietary supplement, particularly for men at
increased risk of prostate cancer. However, its use should be guided by
healthcare professionals and supported by further clinical evidence.
With its
versatility and compatibility with existing therapies, curcumin stands out as a
natural compound that could make prostate cancer treatment more effective, less
toxic, and
more patient-centered.
Read next: Omega-3 fatty acids: a nutritional lever against prostate cancer
About the Author – Carolina Lima
Anaesthesiology specialist
Carolina is a specialist in Anaesthesiology with a deep passion for learning and sharing medical knowledge. Dedicated to advancing the field, Dr. Lima strives to bring fresh, evidence-based insights to the medical community. Viewing medicine not merely as a profession but as a lifelong journey of continuous learning, Dr. Lima is committed to making complex information clear, practical, and useful for healthcare professionals around the world.
